Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Gains from Sales and Divestitures (2020 - 2025)

Historic Gains from Sales and Divestitures for Tango Therapeutics (TNGX) over the last 5 years, with Q3 2025 value amounting to $454414.0.

  • Tango Therapeutics' Gains from Sales and Divestitures rose 7952.8% to $454414.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $454414.0, marking a year-over-year increase of 7952.8%. This contributed to the annual value of $260865.0 for FY2024, which is 59564.0% up from last year.
  • According to the latest figures from Q3 2025, Tango Therapeutics' Gains from Sales and Divestitures is $454414.0, which was up 7952.8% from $433483.0 recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' Gains from Sales and Divestitures registered a high of $454414.0 during Q3 2025, and its lowest value of $37500.0 during Q2 2023.
  • Its 4-year average for Gains from Sales and Divestitures is $236270.1, with a median of $254750.5 in 2021.
  • Per our database at Business Quant, Tango Therapeutics' Gains from Sales and Divestitures plummeted by 6744.62% in 2021 and then skyrocketed by 59564.0% in 2024.
  • Quarter analysis of 4 years shows Tango Therapeutics' Gains from Sales and Divestitures stood at $256598.0 in 2021, then crashed by 85.39% to $37500.0 in 2023, then skyrocketed by 595.64% to $260865.0 in 2024, then soared by 74.2% to $454414.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $454414.0 for Q3 2025, versus $433483.0 for Q2 2025 and $377485.0 for Q1 2025.